http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018062527-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b351d72e7af21be10219cdc65b59f99 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2257 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 |
| filingDate | 2018-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9659e478951ff6ed390fba36cd062a7 |
| publicationDate | 2018-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2018062527-A |
| titleOfInvention | Use of prolactin receptor antagonists and chemotherapeutic agents to treat ovarian cancer |
| abstract | The present invention provides a method for inhibiting the growth of breast cancer triple negative cells that do not express estrogen receptor, progesterone receptor or Her2 / neu in a patient. The present invention relates generally to the field of cancer diagnosis and therapy, particularly to compositions and methods useful in eliminating cancer cells with stem-like properties. The disclosed compositions and methods may also be useful for the management of metastatic breast cancer, ovarian cancer, cervical cancer or endometrial (uterine) cancer, and visualization of cancer cells in a patient. The composition of the present invention includes the human prolactin receptor antagonist G129R. The present invention provides a method of inhibiting the growth of breast cancer triple negative cells that do not express estrogen receptor, progesterone receptor or Her2 / neu in a patient, including administration of a human prolactin receptor antagonist to the patient. [Selection figure] None |
| priorityDate | 2010-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1482.